Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Beigene Ltd Ads (BGNE)

Beigene Ltd Ads (BGNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,354,145
  • Shares Outstanding, K 61,072
  • Annual Sales, $ 198,220 K
  • Annual Income, $ -673,770 K
  • 60-Month Beta 1.14
  • Price/Sales 40.77
  • Price/Cash Flow N/A
  • Price/Book 6.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -4.84
  • Number of Estimates 4
  • High Estimate -3.98
  • Low Estimate -5.35
  • Prior Year -4.52
  • Growth Rate Est. (year over year) -7.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
150.10 +12.95%
on 02/03/20
173.98 -2.55%
on 02/19/20
-0.13 (-0.08%)
since 01/21/20
3-Month
150.10 +12.95%
on 02/03/20
210.35 -19.40%
on 11/25/19
-38.80 (-18.62%)
since 11/21/19
52-Week
113.01 +50.02%
on 06/18/19
210.35 -19.40%
on 11/25/19
+30.69 (+22.10%)
since 02/21/19

Most Recent Stories

More News
BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment...

BGNE : 169.54 (-0.85%)
111 Unveils New Video on The Impact of Chinese Policies to Medical Industry

111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, announced the release of the sixth episode in its 111 Insight series. The title announced today,...

BGNE : 169.54 (-0.85%)
YI : 6.76 (-5.59%)
111 Unveils New Video on the Impact of the Internet and other New Technologies on the Medical Industry

111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, announced the release of the fifth episode in its 111 Insight series. The title announced today,...

BGNE : 169.54 (-0.85%)
YI : 6.76 (-5.59%)
EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT(R) and QARZIBA(R) in Greater China

- SYLVANT and QARZIBA recently listed for fast-track approval in China -

BGNE : 169.54 (-0.85%)
BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment...

BGNE : 169.54 (-0.85%)
JPM : 135.81 (-1.22%)
Leap Therapeutics Surges on License Agreement With BieGene

Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs equity financing deals worth $27 million.

MRK : 82.34 (-0.18%)
BMY : 65.63 (+0.71%)
BGNE : 169.54 (-0.85%)
LPTX : 2.60 (-4.06%)
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted immuno-oncology therapeutics, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company...

BGNE : 169.54 (-0.85%)
LPTX : 2.60 (-4.06%)
BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment

-- Anthony C. Hooper, Former Executive Vice President of Global Commercial Operations at Amgen, Joins BeiGene Board of Directors

BGNE : 169.54 (-0.85%)
AMGN : 222.79 (+0.29%)
BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China

BeiGene's (BGNE) tislelizumab gets an NMPA nod in China for treating patients with classical Hodgkin's lymphoma, having received minimum two prior therapies.

BMY : 65.63 (+0.71%)
BGNE : 169.54 (-0.85%)
INVA : 15.12 (+0.13%)
GH : 88.81 (+1.59%)
ROSEN, NATIONAL TRIAL LAWYERS, Continues to Investigate Securities Claims Against BeiGene, Ltd. - BGNE

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of BeiGene, Ltd. (NASDAQ: BGNE) resulting from allegations that BeiGene...

BGNE : 169.54 (-0.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade BGNE with:

Business Summary

BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.

See More

Key Turning Points

2nd Resistance Point 172.83
1st Resistance Point 171.18
Last Price 169.54
1st Support Level 166.72
2nd Support Level 163.91

See More

52-Week High 210.35
Fibonacci 61.8% 173.17
Last Price 169.54
Fibonacci 50% 161.68
Fibonacci 38.2% 150.19
52-Week Low 113.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar